

Randomised controlled trials comparing VTE and CVD incidence with high dose parenteral EU and PEP versus LHRH agonists and orchiectomy:

BOLD TEXT indicates OR significant at p=0.10

EU = Estradiol undecylate; PEP = Polyestradiol Phosphate; ASA = Aspirin, LHRH = LHRH Agonist; OE = Orchiectomy

Name and location	Sample	Follow-up time	Regimens	OR (95% CI)	Sources
Prospective clinical trial, University of Mainz, West Germany	n = 191 (age range: 51 to 84; mean age: 67.6)	6 months follow-up (? total patient years)	EU 100 mg/month i.m. (n = 96) vs CPA 300 mg/week i.m. (n = 95)	0.78 (0.20 to 3.01) 4.90 (1.58 to 15.16) 2.68 (1.16 to 6.20)	Jacobi et al.,1980 ; Jacobi, Tunn & Senge.,1982 ; Wenderoth & Jacobi.,1983
Extension clinical trial, Ruhr University Bochum, West Germany	n = 39 (age range: ?; mean age: ?)	5 years follow-up (? total patient years)	EU 100 mg/month i.m. (n = 19) vs CPA 100 mg/day p.o. (n = 20)	? ? ?	Namer.,1988 ; Tunn, Radlmaier & Neumann.,1988 ; Schröder & Radlmaier.,2002
FinnProstate-2 clinical trial, Helsinki University Central Hospital, Finland	n = 195 (age range: 55 to 84; mean age: 70.8)	2 years follow-up (? total patient years)	PEP 160 mg/month i.m. (n = 111; n = 71 with ASA) vs OE (n = 72)	0.65 (0.01 to 33.14) 1.30 (0.12 to 14.64) 1.30 (0.12 to 14.64)	Aro et al.,1989 ; Haapiainen, Rannikko & Alfthan.,1990 ; Aro et al.,1991
Prospective clinical trial, Nottingham City Hospital, United Kingdom	n = 117 (age range: ?; mean age: ?)	? months follow-up (? total patient years)	PEP 160 mg/month i.m. (n = 61) vs OE (n = 56)	4.75 (0.22 to 101.08) 1.42 (0.38 to 5.31) 1.96 (0.56 to 6.92)	Bishop et al.,1989
FinnProstate-4 clinical trial, Helsinki University Central Hospital, Finland	n = 147 (age range: 46 to 87; mean age: 72.3)	3 years follow-up (? total patient years)	PEP 160 mg/month i.m. (n = 70) vs LHRH n.a.s. (n = 77)	? ? 0.91 (0.27 to 3.13)	Aro et al.,1993
Zoladex Study Group clinical trial, University of Oulu, Finland	n = 236 (age range: 49 to 100; mean age: 73.0)	~2 years follow-up (484.5 total patient years)	PEP 160 mg/month i.m. (n = 107) vs LHRH s.c. (n = 129)	1.20 (0.02 to 61.22) 2.38 (1.11 to 5.10) 2.38 (1.11 to 5.10)	Lukkarinen & Kontturi.,1994
SPCG-5 clinical trial, Karolinska University Hospital, Sweden	n = 910 (age range: 41 to 93 and mean age: 73.1)	12 years follow-up (? total patient years)	PEP 240 mg/month i.m. (n = 455) vs LHRH s.c. or OE (n = 455)	1.52 (0.67 to 3.41) 1.48 (1.06 to 2.07) 1.52 (1.10 to 2.09)	Hedlund et al.,2002 ; Hedlund et al.,2008 ; Hedlund et al.,2011
FinnProstate-6 clinical trial, Helsinki University Central Hospital, Finland	n = 444 (age range: 45 to 91 and mean age: 73.0)	10 years follow-up (? total patient years)	PEP 240 mg/month i.m. (n = 227) vs OE (n = 217)	5.86 (0.70 to 49.12) 2.02 (0.98 to 4.15) 2.39 (1.21 to 4.72)	Mikkola et al.,1998 ; Mikkola et al.,2005 ; Mikkola et al.,2007